Drug-Induced Urolithiasis - 14/01/15
Doi : 10.1016/S0195-5616(99)50014-4
Carl A. Osborne, DVM, PhD *, Jody P. Lulich, DVM, PhD, Joseph W. Bartges, DVM, PhD, Lisa K. Ulrich, CVT, Lori A. Koehler, CVT, Kathleen A. Bird, CVT, Laura L. Swanson, CVT, Glenn W. Austin, Edwin L. Prien, MD, Kirk U. Steinam, DVM
From the Minnesota Urolith Center, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Minnesota (CAO, JPL, JWB, LKU, LAK, KAB, LLS), St. Paul, Minnesota
Louis C. Herring & Co (GWA), Orlando, Florida
Laboratory for Stone Research (ELP), Newton, Massachusetts
Private Practice (KUS), Manhattan Beach, California
*The Minnesota Urolith Center, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN 55108
Résumé |
Diagnostic and therapeutic drugs may enhance urolithiasis in one or a combination of ways, including: (1) alteration of urine pH in such fashion as to create an environment that increases the solubility of some lithogenic substances, (2) alteration of glomerular filtration rate, tubular reabsorption, and tubular secretion of drugs of endogenous substances so as to enhance promoters or impair inhibitors of urolithiasis, and (3) precipitation (e.g., drugs or their metabolites) to form a portion or all of a urolith.
Le texte complet de cet article est disponible en PDF.© 1999
W.B. Saunders Company. Tous droits réservés.
Vol 29 - N° 1
P. 251-266 - janvier 1999 Retour au numéro
Article précédent
- Canine and Feline Nephrolithiasis : Epidemiology, Detection, and Management
- Sheri J. Ross, Carl A. Osborne, Jody P. Lulich, David J. Polzin, Lisa K. Ulrich, Lori A. Koehler, Kathleen A. Bird, Laura L. Swanson
- Canine Retrograde Urohydropropulsion : Lessons From 25 Years of Experience
- Carl A. Osborne, Jody P. Lulich, David J. Polzin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?